Shots:

• Novartis reports that it has 60 projects in P-II with expected 10+ products to enter in P-III study in 2020 & 2021 while 90% of them are first-in-class or first-in-indication therapies. Novartis emphasizes its focus on innovative medicines- diversification across therapeutic areas and exposure to cutting-edge platforms
• Novartis presents its emerging assets including Iscalimab in transplant & Sjögren’s syndrome- LNP023 in renal diseases & PNH- MBG453 in MDS- and TQJ230 in the reduction of CV risk. The company divulges its expected near-term launches including ofatumumab for relapsing MS- Fevipiprant for Asthma- Radioligand Therapy Lu-PSMA-617 for PC- Adakveo for SCD and Canakinumab in lung cancer
• Novartis is exploring 40+ new indication to maximize the potential of in-line brands- including up to 7 for its Cosentyx and others for Beovu- Piqray and Kisqali and its NIBR team is examining 90+ NMEs including TNO155- being developed for advanced solid tumors with RASG12C mutations

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: GMP News